Priscilla Léon1,2, Geraldine Cancel-Tassin3,4, Sara Drouin3,5, Marie Audouin3,6, Justine Varinot7, Eva Comperat3,4,8, Xavier Cathelineau9, François Rozet9, Christophe Vaessens5, Steven Stone9, Julia Reid10, Zaina Sangale10, Patrick Korman10, Morgan Rouprêt3,4,5, Gaelle Fromond-Hankard4,11, Olivier Cussenot3,4,6. 1. GRC No 5 ONCOTYPE-URO, Institut Universitaire de Cancérologie, Sorbonne Université, 75020, Paris, France. pleon@chu-reims.fr. 2. Academic Department of Urology, CHU Reims, 51000, Reims, France. pleon@chu-reims.fr. 3. GRC No 5 ONCOTYPE-URO, Institut Universitaire de Cancérologie, Sorbonne Université, 75020, Paris, France. 4. CeRePP, 75020, Paris, France. 5. Academic Department of Urology, Hopital Pitie-Salpetriere, AP-HP, Sorbonne Université, 75013, Paris, France. 6. Academic Department of Urology, Hopital Tenon, AP-HP, Sorbonne Université, 75020, Paris, France. 7. Academic Department of Pathology, Hopital Pitie-Salpetriere, AP-HP, Sorbonne Université, 75013, Paris, France. 8. Academic Department of Pathology, Hopital Tenon, AP-HP, Sorbonne Université, 75020, Paris, France. 9. Department of Urology, Institut Mutualiste Montsouris, Université René Descartes, 42 Boulevard Jourdan, 75674, Paris, France. 10. Myriad Genetics, Inc., Salt Lake City, UT, USA. 11. Academic Department of Pathology, CHU Tours, 37000, Tours, France.
Abstract
PURPOSE: Previous studies of the cell cycle progression (CCP) score in surgical specimens of prostate cancer (PCa) in patients treated by radical prostatectomy (RP) demonstrated significant association with time to biochemical recurrence (BCR). In this study, we compared the ability of the CCP score and the expression of PTEN or Ki-67 to predict BCR in a cohort of patients treated by RP. Finally, we constructed the best predictive model for BCR, incorporating biomarkers and relevant clinical variables. MATERIALS AND METHODS: The study population consisted of 652 PCa patients enrolled in a retrospective cohort and who had RP surgery in French urological centers from 2000 to 2007. RESULTS: Among the 652 patients with CCP scores and complete clinical data, BCR events occurred in 41%, and the median time from surgery to the last follow-up among BCR-free patients was 72 months. In univariate Cox analysis, the continuous CCP score and positive Ki-67 predicted recurrence with a HR of 1.44 (95% CI 1.17-1.75; p = 5.3 × 10-4) and 1.89 (95% CI 1.38-2.57; p = 1.6 × 10-4), respectively. In contrast, PTEN expression was not associated with BCR risk. Of the three biomarkers, only the CCP score remained significantly associated in a multivariable Cox model (p = 0.026). The best model incorporated CAPRA-S and CCP scores as predictors, with HRs of 1.32 and 1.24, respectively. CONCLUSION: The CCP score was superior to the two IHC markers (PTEN and Ki-67) for predicting outcome in PCa after RP.
PURPOSE: Previous studies of the cell cycle progression (CCP) score in surgical specimens of prostate cancer (PCa) in patients treated by radical prostatectomy (RP) demonstrated significant association with time to biochemical recurrence (BCR). In this study, we compared the ability of the CCP score and the expression of PTEN or Ki-67 to predict BCR in a cohort of patients treated by RP. Finally, we constructed the best predictive model for BCR, incorporating biomarkers and relevant clinical variables. MATERIALS AND METHODS: The study population consisted of 652 PCa patients enrolled in a retrospective cohort and who had RP surgery in French urological centers from 2000 to 2007. RESULTS: Among the 652 patients with CCP scores and complete clinical data, BCR events occurred in 41%, and the median time from surgery to the last follow-up among BCR-free patients was 72 months. In univariate Cox analysis, the continuous CCP score and positive Ki-67 predicted recurrence with a HR of 1.44 (95% CI 1.17-1.75; p = 5.3 × 10-4) and 1.89 (95% CI 1.38-2.57; p = 1.6 × 10-4), respectively. In contrast, PTEN expression was not associated with BCR risk. Of the three biomarkers, only the CCP score remained significantly associated in a multivariable Cox model (p = 0.026). The best model incorporated CAPRA-S and CCP scores as predictors, with HRs of 1.32 and 1.24, respectively. CONCLUSION: The CCP score was superior to the two IHC markers (PTEN and Ki-67) for predicting outcome in PCa after RP.
Authors: Neal D Shore; Naveen Kella; Brian Moran; Judd Boczko; Fernando J Bianco; E David Crawford; Thaylon Davis; Kirstin M Roundy; Kristen Rushton; Charles Grier; Rajesh Kaldate; Michael K Brawer; Mark L Gonzalgo Journal: J Urol Date: 2015-09-25 Impact factor: 7.450
Authors: Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone Journal: Lancet Oncol Date: 2011-03 Impact factor: 41.316
Authors: Romain Mathieu; Shahrokh F Shariat; Christian Seitz; Pierre I Karakiewicz; Harun Fajkovic; Maxine Sun; Yair Lotan; Douglas S Scherr; Ashutosh Tewari; Francesco Montorsi; Alberto Briganti; Morgan Rouprêt; Ilaria Lucca; Vitaly Margulis; Michael Rink; Luis A Kluth; Malte Rieken; Alexander Bachman; Evanguelos Xylinas; Brian D Robinson; Karim Bensalah; Markus Margreiter Journal: World J Urol Date: 2014-10-26 Impact factor: 4.226
Authors: Antje Krohn; Tobias Diedler; Lia Burkhardt; Pascale-Sophie Mayer; Colin De Silva; Marie Meyer-Kornblum; Darja Kötschau; Pierre Tennstedt; Joseph Huang; Clarissa Gerhäuser; Malte Mader; Stefan Kurtz; Hüseyin Sirma; Fred Saad; Thomas Steuber; Markus Graefen; Christoph Plass; Guido Sauter; Ronald Simon; Sarah Minner; Thorsten Schlomm Journal: Am J Pathol Date: 2012-06-13 Impact factor: 4.307
Authors: Peter J Boström; Anders S Bjartell; James W F Catto; Scott E Eggener; Hans Lilja; Stacy Loeb; Jack Schalken; Thorsten Schlomm; Matthew R Cooperberg Journal: Eur Urol Date: 2015-04-23 Impact factor: 20.096
Authors: Matthew R Cooperberg; Jeffry P Simko; Janet E Cowan; Julia E Reid; Azita Djalilvand; Satish Bhatnagar; Alexander Gutin; Jerry S Lanchbury; Gregory P Swanson; Steven Stone; Peter R Carroll Journal: J Clin Oncol Date: 2013-03-04 Impact factor: 44.544
Authors: Stephen J Freedland; Leah Gerber; Julia Reid; William Welbourn; Eliso Tikishvili; Jimmy Park; Adib Younus; Alexander Gutin; Zaina Sangale; Jerry S Lanchbury; Joseph K Salama; Steven Stone Journal: Int J Radiat Oncol Biol Phys Date: 2013-06-05 Impact factor: 7.038
Authors: Anna Gasinska; Janusz Jaszczynski; Urszula Rychlik; Elżbieta Łuczynska; Marek Pogodzinski; Mikolaj Palaczynski Journal: Pathol Oncol Res Date: 2019-04-15 Impact factor: 3.201
Authors: Tamara L Lotan; Harsimar B Kaur; Daniela C Salles; Sanjana Murali; Edward M Schaeffer; Jerry S Lanchbury; William B Isaacs; Robert Brown; Andrea L Richardson; Olivier Cussenot; Geraldine Cancel-Tassin; Kirsten M Timms; Emmanuel S Antonarakis Journal: Mod Pathol Date: 2021-01-18 Impact factor: 8.209